Kwang Dong signs a Korean exclusive license agreement of female sexual desire disorder treatment

Published: 2017-11-24 08:32:05

Updated: 2017-11-24 08:32:05

Kwang Dong Pharmaceutical(CEO Sung-Won Choi) announced on the 22^nd that it signed a Korean exclusive license agreement of ‘bremelanotide,’ a substance candidate of novel drug developed by U.S. Palatin Technologies for the treatment of sexual desire disorder.

According to Kwang Dong Pharmaceutical, the novel drug substance candidate has shown efficacy of improving symptoms related to its clinic...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.